JAZZ News and Press, Jazz Pharmaceuticals plc From 09/05/22

Summary Avadel Pharmaceuticals goes into the spotlight today. This small biopharma company recently got 'tentative' FDA approval for its flagship drug but is still waiting on one patent challenge to move forward to commercialization. How should investors navigate through this ...

Big technology companies aren't always the portfolio winners that they're cracked up to be. Down by 28% over the past 12 months, shares of Amazon (NASDAQ: AMZN) are performing even worse than the market's decline of 13% in the same period. And with inflation and interest rate hikes ...

Summary Jazz has a monopoly on the market for narcolepsy drugs. Narcolepsy patients require daily medication to keep functioning properly throughout the day. The sales of oxybates can therefore be called stable. Jazz's Vision 2025 expects consolidated sales to grow by double d...

It's been a terrible, horrible, no good, awful past seven months on Wall Street. Most companies are feeling the effects of macroeconomic headwinds such as inflation and supply chain issues, and few are managing to perform well on the market. Thankfully, there are some companies in the b...

Jazz Pharmaceuticals ( NASDAQ: JAZZ ) said it began a new phase 3 trial of cannabis drug Epidiolex (cannabidiol) to treat children and adolescents with Epilepsy with Myoclonic-Atonic Seizures (EMAS). "An EMAS indication would provide support for the use of Epidiole...

Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures PR Newswire Trial is the first randomized, controlled clinical trial evaluating cannabi...

In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill them. Simply put, it means failing to start or intensify a therapy when appropriate, which leads to advanced or chronic disea...

Commercial-stage biopharma Axsome Therapeutics ( NASDAQ: AXSM ) fell ~8% in the pre-market even after the company exceeded Street forecasts with its Q2 2022 financials on Tuesday as the investors focus on the regulatory path for the company’s depression candidate AXS-...

Jazz Pharmaceuticals plc (JAZZ) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Andrea Flynn - Vice President & Head-Investor Relations Bruce Cozadd - Chairman & Chief Executive Officer Dan Swisher - President Rob Ian...

Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q2 Non-GAAP EPS of $4.30 beats by $0.11 . Revenue of $932.88M (+24.1% Y/Y) beats by $30.37M . 2022 total revenue guidance affirmed at $3.5B to $3.7B vs. consensus of $3.6B. "We have achieved our net lever...